The strong survival signal and clean safety profile support a potential registrational path. Watch for FDA Type B meeting outcome and Phase 3 design details. The stock is likely to react positively to these data, but early-phase results in a 24-patient single-arm study carry replication risk.
Price Chart
Executive Summary
NeOnc Technologies reported positive Phase 2a topline results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 48.9% six-month progression-free survival versus a 20% historical benchmark (p=0.0047), and median overall survival was 26.09 months compared to the typical 6-9 months in this salvage setting. The company plans to request a Type B meeting with the FDA to align on a registrational path, which could be a significant catalyst for this $113M market cap clinical-stage biotech.
Key Facts
- Phase 2a met primary endpoint: PFS-6 of 48.9% vs 20% benchmark (p=0.0047)
- Median overall survival 26.09 months from recurrence vs historical 6-9 months
- 5 of 24 patients remain on treatment; one partial response ongoing beyond 114 days
- No major toxicities; adverse events predominantly low-grade
- Company to request Type B FDA meeting for registrational path in recurrent IDH1-mutant high-grade glioma
Financial Impact
No financial data in filing; potential for accelerated approval pathway in an unmet-need setting with no approved targeted therapy
Risk Factors
- Single-arm, open-label study with 24 patients (not powered as confirmatory)
- Results under protocol-specified RANO criteria were not significant (PFS-6 25.8%, p=0.276)
- FDA may not agree on proposed registrational design or endpoints
- Early-phase results frequently fail to replicate in larger controlled trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-008654 |
| Document: neonctechnologies_8k.htm | 0001829126-26-008654 |
| Document: neonctechnologies_ex99-1.htm | 0001829126-26-008654 |
| Document: 0001829126-26-008654-index-headers.html | 0001829126-26-008654 |
| Document: 0001829126-26-008654-index.html | 0001829126-26-008654 |
| Document: 0001829126-26-008654.txt | 0001829126-26-008654 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $3.27 | awaiting T+60 | — | $2.79 (−14.60%) |
Oct 15, 2026 11d ago | 8-K | $2.70 | awaiting T+60 | — | $2.79 (+3.43%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $2.79 (−16.14%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $2.79 (−18.10%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $2.79 (−6.60%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $2.79 (+23.70%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $2.79 (+23.70%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $2.79 (−40.26%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $2.79 (−49.50%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $2.79 (−19.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers